glp 1 agonists drugs Evolution of GLP‐1 Receptor for Diabetes Treatment America's Poison Centers - GLP-1

The US Food and Drug Administration on Monday approved a generic version of the daily injectable GLP-1 medicine liraglutide for people with type 2 diabetes, opening the door for lower-priced options to reach the market and help address a shortage.

The Latin America Glucagon-like Peptide-1 (GLP-1) Agonists Market worth USD 2.91 billion in 2026 is growing at a CAGR of 8.24% to reach USD 4.33 billion by 2031

This means that FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed.

In addition, WHO included GLP-1 therapies on its Essential Medicines List (EML)

Given the potential for increased INR variability, clinicians may consider increasing INR monitoring frequency following GLP-1 RA initiation.

Furthermore,...